CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen BioNTech BNTX

Verkoop
 Koop

BioNTech live grafieken

5m 15m 30m 1h 4h 1d 1w

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Frances Wang 2024 Dec 29, 16:00

Stock market today: Most Asian stocks fell after US equities declined

Stocks
Frances Wang 2024 Dec 29, 16:00

MicroStrategy joins Nasdaq-100 index: MSTR stock performance analysis 2024

Cryptocurrencies Stocks
Dyogenes Diniz 2024 Dec 29, 16:00

Morning Note: Key Levels & Data Driving the Last Monday of 2024

Forex Morning Note USD
Closing 2024
Dyogenes Diniz 2024 Dec 26, 17:00

Week ahead: Closing 2024 and First Economic data from 2025

Forex Indices
Tesla soars
Dyogenes Diniz 2024 Dec 26, 17:00

Morning Note: Tesla Soars, AUDUSD Hits Key Support, Oil & SP500 Insights

Forex Oil S&P 500
Frances Wang 2024 Dec 26, 16:00

Nikkei 225 up 1.39%: Japanese Stocks Rise Following Yen's Continued Weakness

Stocks
Frances Wang 2024 Dec 25, 16:00

Asian stock market today: most Asian stocks rise amid thin holiday trading

Stocks
Frances Wang 2024 Dec 25, 16:00

Stock market today: Nasdaq, S&P 500, Dow surge ahead of Christmas break

Stocks

Info

Spread

0.7801

Spread (%)

0.8393 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Vrijdag

13:31 - 19:59

Maandag

13:31-19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

Donderdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

23202729984

Uitstaande aandelen

240392992

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

2022-06-17

Ex-dividenddatum

2022-06-02

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-3.03

Meer informatie over dit instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering

Handel nu

Handel nu

Handel nu

Handel nu
Gerelateerde instrumenten
Trustpilot
RequestMessages59TimelineExceptionsViews0RouteQueries0Models0MailsGateSession
SettingsRequest history38.1.18PHP Version29.59msRequest Duration2MBMemory UsageGET csrf
status
200 OK
full_url
https://web-qa.staging.markets.com/csrf
controller_action
Closure
Theme
Open Button Position
Hide Empty Tabs
Autoshow
Reset to defaults
status
200 OK
full_url
https://web-qa.staging.markets.com/csrf
action_name
controller_action
Closure
uri
GET csrf
file
routes/web.php:26-30
middleware
web
duration
30.12ms
peak_memory
2MB
response
application/json
request_format
html
request_query
[]
request_request
[]
request_headers
  0 of 0   
array:14 [▼
  "cookie" => array:1 [▶
    0 => "mktv4_ip_override=nl; mktloc=eyJpdiI6IjkzN1RGdzVmYjNmR21QNmlhSTJsZWc9PSIsInZhbHVlIjoiY25RRDZTejFHbU9XaDQ1TkxiMStLdWNUc2hTd0pBS085NnlQbThndG5qODh2bW5nM2RueVcwQVpBRVBiVXU5cSIsIm1hYyI6ImVkYzEwZWY0NjkyNGVjYzY1ZTI4ZjFhMzlkZTEyYWE0MzdkMWI3ZTU1YTc0ZGY1ZTBiM2RhYjkzZTk0Mjg4YmYiLCJ0YWciOiIifQ%3D%3D; intent_group=%252Fnl%252Finstrument%252Fmstanley%252F; intent_instrument=mstanley; firstURL=https://web-qa.staging.markets.com/my/instrument/elililly/; lastURL=https://web-qa.staging.markets.com/my/instrument/elililly/; XSRF-TOKEN=eyJpdiI6InZWcmR1cSt6SVJBY0FTaTJLK0YvVUE9PSIsInZhbHVlIjoiQmdYbFFFWkt0T0xGaWswK0ZpQ2l1NDBSV3JlSVA0T0VMTFdQQWdzemRmVVVmanpnYXJRckFGbzlFUElJOTBHQ1kwMmF0N3ZRb1Vxb2FrZXpKWFZnMGpDOUdzSGJMUEI5c3hweUVKbmVPK3NVWWVJUW9MTWhOdXBDcm9lSFRIbVEiLCJtYWMiOiI3NTUyMWZiOTI2OTc5NjUzNWRkNTAxZTNkNjNmOWY5NTJlZTc3NDc3Y2QyOGFjNzdmNmQ4MzBiMzg4MjAyNTk0IiwidGFnIjoiIn0%3D; laravel_session=eyJpdiI6Im5pcCs5SlJNa3B0ckUvdS9qU3lDYlE9PSIsInZhbHVlIjoianZsNkJ0S2JLR1c1ajlSb2hKU28rQUtPTjF4UCtvYnQwbC8wVlc4QS92c1R5b2cydFJDMm5oYmYvanMrdjU2VnpuZHJyOFF1dXIrTTFMazNobFdpUUJ4TDREcENGUlZUZkkrOTVYV3JnS0p3eGZrcVMyenhzY1pDcmd0OGFxRWYiLCJtYWMiOiI0YmU5YTkwYTVlZGI1OTk4OWQwYmZkMDQzMGUxYTk3ZjQxZWYwZjUyNDY1MzE0MjQ2YzgyZTY5YTY0MTU2MWNhIiwidGFnIjoiIn0%3D ◀mktv4_ip_override=nl; mktloc=eyJpdiI6IjkzN1RGdzVmYjNmR21QNmlhSTJsZWc9PSIsInZhbHVlIjoiY25RRDZTejFHbU9XaDQ1TkxiMStLdWNUc2hTd0pBS085NnlQbThndG5qODh2bW5nM2RueVcwQVp ▶"
  ]
  "accept-encoding" => array:1 [▶
    0 => "gzip, deflate, br, zstd"
  ]
  "sec-fetch-dest" => array:1 [▶
    0 => "empty"
  ]
  "sec-fetch-mode" => array:1 [▶
    0 => "cors"
  ]
  "sec-fetch-site" => array:1 [▶
    0 => "same-origin"
  ]
  "accept" => array:1 [▶
    0 => "*/*"
  ]
  "sec-ch-ua-mobile" => array:1 [▶
    0 => "?0"
  ]
  "sec-ch-ua" => array:1 [▶
    0 => ""HeadlessChrome";v="129", "Not=A?Brand";v="8", "Chromium";v="129""
  ]
  "user-agent" => array:1 [▶
    0 => "Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)"
  ]
  "sec-ch-ua-platform" => array:1 [▶
    0 => ""Windows""
  ]
  "cache-control" => array:1 [▶
    0 => "no-cache"
  ]
  "pragma" => array:1 [▶
    0 => "no-cache"
  ]
  "connection" => array:1 [▶
    0 => "keep-alive"
  ]
  "host" => array:1 [▶
    0 => "web-qa.staging.markets.com"
  ]
]
request_cookies
  0 of 0   
array:8 [▼
  "mktv4_ip_override" => null
  "mktloc" => "us,us"
  "intent_group" => null
  "intent_instrument" => null
  "firstURL" => null
  "lastURL" => null
  "XSRF-TOKEN" => "XA7V5X8Bj2TAz3FavUyrYkRWT96h0bRBRzoEq5Ff"
  "laravel_session" => "ufFsg7mliolMelT91RIVxt1pavBDB6pskkoycCF9"
]
response_headers
  0 of 0   
array:3 [▼
  "cache-control" => array:1 [▶
    0 => "no-cache, private"
  ]
  "date" => array:1 [▶
    0 => "Sun, 13 Apr 2025 17:11:05 GMT"
  ]
  "content-type" => array:1 [▶
    0 => "application/json"
  ]
]
session_attributes
  0 of 0   
array:4 [▼
  "_token" => "XA7V5X8Bj2TAz3FavUyrYkRWT96h0bRBRzoEq5Ff"
  "PHPDEBUGBAR_STACK_DATA" => []
  "_previous" => array:1 [▶
    "url" => "https://web-qa.staging.markets.com/widget/tradingcentralinfo/nl/BNTX:NASDAQ?scheme=light"
  ]
  "_flash" => array:2 [▶
    "old" => []
    "new" => []
  ]
]
    • Booting (24.9ms)time
    • Application (4.68ms)time
    • Routing (552μs)
    • 1 x Booting (84.14%)
      24.90ms
      1 x Application (15.82%)
      4.68ms
      1 x Routing (1.87%)
      552μs
      0 templates were rendered
        uri
        GET csrf
        middleware
        web
        uses
        Closure(Request $request) {#347 class: "Illuminate\Routing\RouteFileRegistrar" this: Illuminate\Routing\RouteFileRegistrar {#344 …} file: "/var/www/website/qa/laravel/routes/web.php" line: "26 to 30" }
        file
        routes/web.php:26-30
        0 statements were executed0μs
              _token
              XA7V5X8Bj2TAz3FavUyrYkRWT96h0bRBRzoEq5Ff
              PHPDEBUGBAR_STACK_DATA
              []
              _previous
              array:1 [ "url" => "https://web-qa.staging.markets.com/widget/tradingcentralinfo/nl/BNTX:NASDAQ?sc...
              _flash
              array:2 [ "old" => [] "new" => [] ]
              ClearShow all
              Date ↕MethodURLData
              #12025-04-13 17:11:02GET/nl/instrument/biontech/5967
              #22025-04-13 17:11:05GET/params/ (ajax)
              #32025-04-13 17:11:05GET/csrf/ (ajax)